vincristine / Generic mfg. - LARVOL DELTA

Ulcerative Necrobiosis Lipoidica in the Setting of Oropharyngeal Epstein-Barr Virus Positive Diffuse LargCell Lymphoma and Glucose-6-Phosphate Dehydrogenase Deficiency: A Case Report (AAD 2026) - "Anti-inflammatory topical clobetasol 0.05% ointment was initiated as well as a saline based solution containing hypochlorous acid for wound cleansing. Due to secondary infection, the patient’s topical regimen was modified to include gentamicin 0.1% ointment and mupirocin 2% ointment followed by eventual broad-spectrum IV antibiotics. Notably, dapsone was avoided due to known G6PD as well as other immunosuppressants in the setting of DLBCL and ongoing chemotherapy with rituximab, cyclophosphamide, doxorubicin, (vincristine), and prednisone (R-CHOP) which had induced neutropenia and thrombocytopenia...Additionally, pegfilgrastim and platelet infusions for neutropenia and thrombocytopenia were administered after initiating R-CHOP. The noninfectious granulomatous reactions may have been an early sign of the underlying lymphoma, suggesting DLBCL as a contributing factor to NL disease pathogenesis."

Case report • Clinical • B Cell Lymphoma • Diabetes • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Metabolic Disorders • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Immunodeficiency • Thrombocytopenia

Comparing Incidence of Febrile Neutropenia Following HyperCVAD Cycle 4 Part B vs. Previous Cycles: Evaluating Risk vs. Benefit of Final Cycle Omissions or Dose Reductions (HOPA 2026) - "Background/Rationale The HyperCVAD regimen, which alternates between two cytotoxic components—Part A (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and Part B (high-dose methotrexate and cytarabine)—is a cornerstone of therapy for adult patients with acute lymphoblastic leukemia (ALL) and Burkitt's lymphoma, producing high complete remission rates...Results Results are pending at the time of abstract submission. ConclusionsConclusions are pending completion of data analysis."

Acute Lymphocytic Leukemia • Burkitt Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Lymphoma • Neutropenia

Evaluation of outpatient administration of dose adjusted EPOCH-R using a single-bag 96-hour infusion of etoposide phosphate, vincristine, and doxorubicin (HOPA 2026) - "Background/Rationale: A component of DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) includes a 96-hour continuous infusion of etoposide, doxorubicin, and vincristine.1 To facilitate outpatient administration of DA-EPOCH-R, previous experiences reported single- or two-day bags of etoposide, doxorubicin, and vincristine due to the concentration dependent solubility and stability of etoposide, which requires additional infusion center visits for bag changes.2-10 Etoposide phosphate is a water-soluble prodrug of etoposide with improved stability. Results pending."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Efficacy of blinatumomab use in B-cell acute lymphoblastic leukemia (ALL) patients with discordant minimal residual disease (MRD) monitoring assays (HOPA 2026) - "Eligible patients received HyperCVAD as induction therapy, consisting of alternating A cycles (cyclophosphamide, mesna, doxorubicin, vincristine, and dexamethasone) and B cycles (high-dose methotrexate and cytarabine). The primary outcome was complete MRD response by NGS following one to two cycles of blinatumomab, assessed through manual chart review. Results/Discussion/Conclusion (State if not available): This study is ongoing therefore results, discussion, and conclusions are not yet available."

Clinical • Discordant • Minimal residual disease • Residual disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia

Evaluation of Procarbazine, Lomustine, and Vincristine versus Procarbazine and Lomustine versus Temozolomide in Patients with Oligodendroglioma (HOPA 2026) - "Conclusions pending."

Clinical • Brain Cancer • Glioma • Leukopenia • Neutropenia • Oligodendroglioma • Solid Tumor • Thrombocytopenia

Impact of Vincristine Omission on Patient Outcomes in High Grade B-Cell Lymphomas (HOPA 2026) - "Standard first line therapy includes R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and other intensified regimens for select cases. One hundred and three patients were included in the final analysis; 60% (n=62) were male and 87% (n=90) were Caucasian. Median age at treatment initiation was 63 years. Overall, 90% of patients were diagnosed with DLBCL (n=93) and 73% received R-CHOP (n=75)."

Clinical • B Cell Lymphoma • Burkitt Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Adult-onset Hydroa Vacciniforme-like Lymphoproliferative Disorder: Case Report and Insights into Virology, Immunophenotype, and Treatment Outcomes. (AAD 2026) - "She was treated with azathioprine, prednisone, vincristine, L-asparaginase, methotrexate, and phototherapy, achieving only partial improvement after eight months. Adult-onset HVLL remains an underrecognized but highly aggressive EBV-driven disorder. Early identification, prognostic stratification using EBV load and immunophenotypic markers, and timely consideration of hematopoietic stem cell transplantation are critical to improving outcomes."

Case report • Clinical • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Hematological Disorders • Infectious Disease • CD20 • CD4 • CD8 • GZMB • NCAM1 • TNFRSF8

Sequential 3D functional profiling shows preserved drug resistance and sensitivity profiles after neoadjuvant treatment in an ovarian cancer patient (AACR 2026) - "VAC (vincristine, actinomycin, and cyclophosphamide) demonstrated high cytotoxic and antiproliferative efficacy before (0.85, [0.75-0.90], and 0.97 [0.92-0.99]) and after therapy (0.73 [0.64-0.78], and 0.99 [0.94-1.00]). Interestingly, the PARP-inhibitors olaparib and rucaparib showed limited cytotoxicity (0.10 [0.08-0.12] and 0 [0-0.08]) but pronounced antiproliferation (0.60 [0.53-0.70] and 0.58 [0.49-0.74]) before the treatment with no material change after it.ConclusionsSequential ex-vivo multiplexed profiling of this advanced ovarian cancer revealed that neoadjuvant carboplatin paclitaxel minimally altered cytotoxic and antiproliferative drug response sensitivity and resistance patterns to VAC and PARP inhibitors...Published October 2014 [3] Apfel C et al., High-throughput multiplexed sensitivity and resistance assay. US Patent US 12,312,631 B1"

Clinical • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

QW-5-70 targets the colchicine site to overcome multidrug resistance and shows potent antitumor activities (AACR 2026) - "Across a panel of NB and prostate cancer lines, QW-5-70 maintained subnanomolar activity and remained effective in vincristine-resistant BE2C/VCR and paclitaxel-resistant PC-3/TxR cells. Combination testing revealed strong quantitative synergy with DFMO in viability assays and marked increases in apoptosis with reduced clonogenic survival when paired with DFMO or the Aurora A inhibitor MLN8237. Collectively, QW-5-70 is a potent CBSI that circumvents P-gp-associated resistance, triggers mitotic arrest and apoptosis, and achieves robust antitumor activity in multidrug-resistant tumor models with acceptable tolerability, supporting its further preclinical development alone and in combination with other drugs."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Neuroblastoma • Oncology • Prostate Cancer • Solid Tumor

Targeting KMT2C induces paralog synthetic lethality in KMT2D null DLBCL through DREAM targets regulation (AACR 2026) - "We observed that inhibitors targeting CBP/p300 and chemotherapy agents like vincristine and doxorubicin combined with KMT2C loss drive deeper responses in KMT2D mutant models. Taken together, our data demonstrate that B cell lymphoma carrying KMT2D mutations are addicted to the residual KMT2C activity and suggest that targeting KMT2C as a monotherapy or in combination may benefit patients with KMT2D loss."

Synthetic lethality • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • DYRK1B • KMT2C • KMT2D

Developing zebrafish avatars for pediatric sarcomas to support functional precision oncology (AACR 2026) - "CellTiter-Glo assays at 34 °C, the incubation temperature required for zPDX experiments, confirmed that RD cells retain drug sensitivity under these conditions: dactinomycin (DAC) significantly reduced RD viability at low nanomolar concentrations (≥10 nM), whereas vincristine (VIN) was effective at 2-10 nM...Guided by media described for zPDX, we developed an enriched medium containing HEPES, glutamine, MEM-NEAA, B27, nicotinamide, ITS, Y-27632, SB202190, N-acetylcysteine, and EGF/FGF with reduced serum...Together, these preliminary data define robust survival and engraftment parameters for RMS xenografts in zebrafish, validate the feasibility of this platform for rapid chemotherapy response readouts, and establish an optimized injection medium that enables even challenging sarcoma subtypes to persist in vivo. These advances provide the foundation for extending this platform to primary pediatric sarcomas, including osteosarcoma, to generate zebrafish avatars for..."

Clinical • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • FGF

CyTOF analysis of targeted therapy in addition to standard of care against Ewing sarcoma tumor subpopulations (AACR 2026) - "SOC involves chemotherapy using alternating cycles of Vincristine, Doxorubicin, Cyclophosphamide (VDC) with Ifosfamide and Etoposide (IE). We have identified that the combination of romidepsin with IE, but not IE alone, leads to an increase in DNA damage in the EWS:FLI1low and cancer stem cell populations. This suggests that the addition of romidepsin to SOC may improve treatment efficacy against subpopulations of tumor cells that are known to be chemoresistant. Further, this study highlights the use of CyTOF to assess treatment effects within ES tumor subpopulations to identify therapies that may be more effective against chemoresistant populations."

Clinical • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • EWSR1 • FLI1

Senescence-associated secretory phenotype drives PGCC's lifecycles and blastomere-like reprogramming to promote therapeutic resistance (AACR 2026) - "While prior studies have characterized their senescent-like phenotypes and capacity for developmental reprogramming, two core questions remain poorly understood, including the temporal dynamics governing PGCC's lifecycle progression and the precise mechanistic role of senescence in shaping their biology. We induced PGCC formation using vincristine (VCR), a mitotic destabilizer, and tracked their lifecycle via live-cell fluorescence imaging... Our work delineates PGCCs' lifecycle evolution and establishes SASP as a key driver of their lifecycle and the emergence of aggressive, therapy-resistant progeny, bridging senescence, developmental reprogramming, and cancer progression."

Oncology • CXCL8 • IL1B • IL6

A panel of patient-derived organoid models from rare cancers for high-throughput preclinical pharmacology studies (AACR 2026) - "Under assay conditions, the organoid models exhibited diverse morphologies and varied growth kinetics with doubling times ranging from 48 - 363 h with an average of 129 h. Among the patients that received prior chemotherapy, four had a partial response as the best outcome, two of which were sarcoma patients treated with regimens including doxorubicin, vincristine, and etoposide...A patient with lip/oral cavity squamous cell carcinoma partially responded to a regimen including temozolomide and the corresponding organoid demonstrated ≥1 log of cytotoxicity following exposure to temozolomide and other drugs below the clinical Cmax. A patient with stomach adenocarcinoma partially responded to a regimen with 5-fluorouracil and cisplatin, but the organoid was minimally sensitive to these drugs. However, genomic characterizations of the tumor tissue indicated an amplification of ERBB2 and the organoid demonstrated sensitivity to the ERBB2 inhibitors neratinib, dacomitinib, and..."

Preclinical • Gastric Adenocarcinoma • Oncology • Oral Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • BRAF • PIK3CA

Evolving toward precision oncology: Leveraging collateral drug responses for personalized second-line osteosarcoma treatment (AACR 2026) - "Objective: We aimed to model the evolution of chemoresistance to methotrexate, doxorubicin, and cisplatin (MAP) in vitro and to characterize collateral drug sensitivity and resistance patterns over time, potentially informing second-line treatment strategies in chemo resistant primary or recurrent disease. Five evolutionary replicates of MG63.3 osteosarcoma cells were treated with six complete cycles of pulsed, clinically relevant doses of cisplatin and doxorubicin, alternating with methotrexate...Collateral resistance emerged to etoposide, vincristine, and topotecan, while sensitivity increased to gemcitabine, cabozantinib, and palifosfamide... Our model reveals temporally dynamic, heterogeneous collateral responses during the development of chemoresistance to MAP in osteosarcoma. While cross-resistance to several agents emerged, collateral sensitivity to gemcitabine and cabozantinib supports a second line use for these agents. These data may inform rational sequencing..."

Clinical • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

LEDGF/p75 drives chemoresistance in CML via JAK/STAT pathway modulation (AACR 2026) - "In KMT2A-wild-type (WT) AML cell lines U-937 and Kasumi-1, LEDGF/p75 depletion did not alter cytarabine sensitivity and the same trend was observed in WT T-ALL cell lines Jurkat and SupT-1...Interestingly, LEDGF/p75 KD in two WT KMT2A CML cell lines, K-562 and JUR-MK1, led to a significant reduction in proliferation upon vincristine treatment (IC50 K-562 Mock/KD: 2.61 ± 0.10 nM / 0.81 ± 0.09 nM and IC50 JUR-MK1 Mock/KD: 3.93 ± 0.35 nM / 2.37 ± 0.30 nM) and increased apoptosis with elevated caspase3. Treatment of K-562 cells with BCR-ABL inhibitors Imatinib and Ponatinib also showed decreased proliferation upon LEDGF/p75 depletion...Taken together, our result indicates that the role of LEDGF/p75 in therapy resistance is context dependent and varies across leukemic subtypes. We identify a previously unknown function of LEDGF/p75 in mediating drug resistance in CML cells acting through the JAK/STAT Pathway."

Breast Cancer • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Prostate Cancer • Solid Tumor • T Acute Lymphoblastic Leukemia • ABL1 • BCL2A1 • BCL2L1 • BCR • CASP3 • KMT2A • STAT2 • STAT5

Efficacy of Aprepitant for Nausea and Vomiting Induced by CHOP/R-CHOP or Pola-R-CHP Chemotherapy. (PubMed, Anticancer Res) - "Doublet antiemetic therapy may be an appropriate treatment option for patients with NHL receiving CHOP/R-CHOP and Pola-R-CHP therapy. Furthermore, a risk-based approach may be more suitable than routine triplet prophylaxis for these regimens."

Journal • Retrospective data • Chemotherapy-Induced Nausea and Vomiting • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Rare Case Report of Primary Hepatic Lymphoma Complicated by Hemophagocytic Lymphohistiocytosis. (PubMed, J Gastrointestin Liver Dis) - "The second-cycle chemotherapy regimen was modified to the R-miniCHOP protocol...Similar to other hematological lymphomas, PHL may also secondarily develop HLH. Early recognition, diagnosis, and intervention are critical to improving prognosis."

Journal • Anorexia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Fatigue • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Rare Diseases • Solid Tumor • Thrombocytopenia

Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay. (PubMed, Epigenomes) - "Our findings show that many anticancer therapy agents modulate the epigenetic landscape of cancer cells, providing a rationale for expanding their therapeutic applications and enhancing the efficacy of combination strategies by overcoming epigenetically driven chemoresistance."

IO biomarker • Journal • Oncology

Investigating the effect of SGLT2 inhibitor dapagliflozin on acute lymphoblastic leukemia in obese mice (AACR 2026) - "DAPA showed synergistic effects with chemotherapy vincristine (VCR) in vitro (Table)...Developing medication-based alternatives to diet/exercise interventions is important to ensure all patients with ALL can benefit from metabolic-interventions. Our study shows that SGLT2 inhibition is effective in vitro, but in vivo data imply it may not be a viable option for improving ALL treatment outcome."

Preclinical • Acute Lymphocytic Leukemia • Breast Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Prostaglandin E2 signaling promotes adverse survival outcome in B-cell acute lymphoblastic leukemia (AACR 2026) - "Additionally, we observed that PGE2 conferred modest resistance in vitro to vincristine and daunorubicin chemotherapies. Overall, our data shows that adipose tissue PGE2 can upregulate genes that are associated with a worse prognosis in ALL patients. Further work is needed to test whether adipose tissue PGE2 is a contributing factor for worse ALL outcomes in obese patients."

Adverse events • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • TNFSF11

Development of a collection of cell lines from a genetically engineered mouse model of DICER1 syndrome-associated sarcoma for therapeutic assessment (AACR 2026) - "IVADo regimen (ifosfamide/cyclophosphamide, vincristine, actinomycin-D, doxorubicin) and CDK4/6 inhibitor were selected to treat the cells...Considering that the KRAS-mutant lung cancer cells have been reported to be hypersensitive to CDK4/6 inhibitor, we tested palbociclib sensitivity and found that only one out of two Kras-mutant cell lines was sensitive to palbociclib... We validated that HDT tumors predominantly express the Dicer1IIIb-mutant transcript and most tumors were quadriphasic (epithelial, undifferentiated blastema, stromal cells, and rhabdomyoblastic cells) with no to variable amounts of anaplastic sarcoma components. From these murine HDT tumors, we have successfully derived five HDT cell lines (HDT298, HDT340, HDT366, HDT546, and HDT1003 cell lines). Some of these cell lines have aberrant p53 expression (or p53 mutation) and Kras mutation, confirming their resemblance to human DICER1-sarcoma."

Preclinical • Lung Cancer • Oncology • Sarcoma • Solid Tumor • DICER1 • KRAS • TP53

Clinical, Pathologic, and Molecular Characteristics of Primary Cutaneous Gamma-Delta T-Cell Lymphoma Mimicking Subcutaneous Panniculitis-like T-cell Lymphoma: A Case Series (USCAP 2026) - "HLH, hemophagocytic lymphohistiocytosis; LE, lower extremity; UE, upper extremity; LAD, lymphadenopathy; BMBx, bone marrow biopsy; MTX, methotrexate; TCS, topical steroids; NB-UVB, narrow-band UVB; ICE, ifosfamide, carboplatin, etoposide; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP plus etoposide; SCT, stem cell transplant; CTD, connective tissue disease; c/f, concerning for; ddx, differential diagnosis; sx, symptoms. This study confirms that PCGDTCL with a subcutaneous pattern can have pathologic features fully overlapping with SPTCL, and emphasizes that a subset of SPTCL-like PCGDTCL may exhibit a more indolent clinical course. Additional studies with a larger cohort are needed to confirm the prognostic significance of this variant."

Clinical • Dermatitis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Indolent Lymphoma • Inflammatory Arthritis • Lupus • Lymphoma • Obesity • Rare Diseases • T Cell Non-Hodgkin Lymphoma • CDKN2A • CDKN2B • DNMT3A • KMT2D • KRAS • POT1 • TNFAIP3

Spectrum, Trends and Patterns of Drug Induced Liver Injury (DILI) in a Comprehensive Cancer Center in the United States (USCAP 2026) - "Group 3 comprised tamoxifen (n=4) for breast carcinoma, 3 showed steatotosis/ stetohepatitis [Fig 2], without underlying metabolic syndrome; the fourth patient with no biopsy changes had metabolic syndrome...Results Table: Abbreviations: ICI, immune checkpoint inhibitors; RCC, renal cell carcinoma; HCC, hepatocellular carcinoma; CA, carcinoma; MCRC, metastatic colorectal carcinoma; SCC, squamous cell carcinoma; HL, Hodgkin lymphoma; Pembro, pembrolizumab; Ipi, ipilimumab; Nivo, nivolumab; Ab, antibody; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; SH, stetohepatitis; DLBCL, diffuse large B cell lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; CHOP, cyclophosphamide, hydroxydaunorubicine,oncovin, prednisolone; CAR-T, chimeric antigen receptor T-cell therapy; SOS, sinusoidal obstruction syndrome Figure 1: Click to view full size Figure 2: Click to view full size The findings reflect evolving trends in therapeutic management of..."

B Cell Lymphoma • Breast Cancer • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hepatology • Hodgkin Lymphoma • Liver Failure • Lymphoma • Mantle Cell Lymphoma • Metabolic Disorders • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma

Chemotherapy-associated Optic Neuropathy in a Patient with Chronic Myeloid Leukemia and Hepatitis B: A Diagnostic Challenge. (PubMed, Ann Afr Med) - "We describe the case of a 32-year-old man diagnosed with chronic myeloid leukemia (CML) and chronic hepatitis B, who developed acute, painless visual loss in the left eye during treatment with a combination of intrathecal methotrexate and cytarabine, vincristine, bortezomib, and ponatinib. This case underscores the need to recognize neurotoxic optic neuropathy as a potential adverse effect in patients receiving multiple chemotherapeutic agents. Timely identification through coordinated, multidisciplinary evaluation is key to distinguishing toxic damage from other causes, particularly in immunocompromised individuals, and may improve outcomes by enabling early management."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Hepatitis B • Immunology • Infectious Disease • Leukemia • Ocular Inflammation • Oncology • Ophthalmology • Optic Neuritis • Pain